Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme

Trial Profile

Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Bortezomib (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 30 Jun 2018.
    • 08 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
    • 07 Jan 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top